|
|
1 Breakfast Creek Road, Newstead
Brisbane, Queensland 4006 Australia
phone:61-7-3250 1200
fax:61-7-3250 1299
|
|
| Symbol |
PEP |
| Exchange |
ASX |
| Founded |
0 |
| Employees |
|
|
|
| www.peplin.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Developing a novel product for the treatment of skin cancer
|
|
| Management |
| Michael Aldridge, Chief Executive Officer; Cheri Jones, Vice President, Regulatory Affairs; Philip Moody, Chief Financial Officer & Vice President, Finance and Operations; Arthur Bertolino, Chief Medical Officer and Vice President, Medical Affairs; David Smith, Company Secretary & Director, Finance; Peter Welburn PhD, General Manager, Australia, CSO & Vice President, Research & Development |
| |
|
|
|
|
|
|
|
| Keywords |
| cancer, leukemia, bladder cancer,
non-melanoma, skin cancer |
|
|
|
| Description |
|
Peplin Limited (Peplin) is a public company focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Peplin is listed on the Australian Stock Exchange (ASX:PEP). |
|
| Products / Services |
Peplin has three products in various stages of pre-clinical and clinical development. These are each based on different formulations of its lead compound PEP005. Each product will target bladder cancer, leukemia and non-melanoma skin cancer.
|
|
| Technology / Differentiation |
| Peplin's core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
